[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 2 sources · 20 days · First seen · Last updated

Jazz Pharmaceuticals Ziihera oncology developments

Overview

In August 2026, Jazz Pharmaceuticals and Purple Biotech reported significant developments in oncology. Jazz Pharmaceuticals published Phase 3 trial results for Ziihera (zanidatamab-hrii) in the New England Journal of Medicine, showing improved progression-free and overall survival for patients with HER2-positive locally advanced or metastatic gastro-esophageal adenocarcinoma. Concurrently, Purple Biotech reported its second-quarter financial results and presented preclinical data for its IM1240 candidate.

Following these clinical developments, Jazz Pharmaceuticals announced the U.S. commercial launch of Ziihera after receiving FDA approval. The therapy is approved for first-line treatment of HER2-positive unresectable, locally advanced, or metastatic gastroesophageal adenocarcinoma, either in combination with tislelizumab and platinum-containing chemotherapy or with chemotherapy alone, depending on the patient's HER2 status.

Entities

Tevimbra (tislelizumab) · FDA · Jazz Pharmaceuticals · Ziihera (zanidatamab‑hrii) · IM1240

Timeline

  1. 17 days ago

    [BUSINESS] 2 sources
    Jazz Pharmaceuticals launches Ziihera following FDA approval for GEA

    Jazz Pharmaceuticals is launching Ziihera (zanidatamab) in the U.S. following FDA approval for first-line HER2-positive gastroesophageal adenocarcinoma (GEA).

  2. about 1 month ago

    [BUSINESS] 3 sources
    Jazz Pharmaceuticals and Purple Biotech announce major oncology developments

    Jazz Pharmaceuticals' Ziihera trial shows strong survival gains in HER2+ gastro‑esophageal cancer, while Purple Biotech reports solid Q2 finances and promising preclinical data for its IM1240 antibody.

Sources

seekingalpha.com · stocknews.com